DCRI Selected as Clinical Trials Data Coordinating Center for NIH RECOVER Long COVID Initiative
The Duke Clinical Research Institute (DCRI) has been named the Clinical Trials Data Coordinating Center for large-scale national research studies aimed at understanding and improving the treatment of long COVID.
CRISPR Technology Demonstrates Success in Preventing and Treating COVID
In what is believed to be a first, a research team led by Duke Health has demonstrated a way to use CRISPR technology to successfully prevent and treat COVID infections.
Study Finds No Benefit to Taking Fluticasone Furoate for COVID-19 Symptoms
A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no symptomatic or clinical benefit to taking fluticasone furoate for the treatment of mild-to-moderate COVID-19 symptoms.
Monoclonal Antibody Treatment Reduced Deaths in Hospitalized COVID Patients
A monoclonal antibody treatment taken by patients hospitalized with COVID-19 did not improve recovery time but did reduce deaths, according to a study published July 8 in The Lancet Respiratory Medicine.
Study Finds No Benefit to Taking Ivermectin for COVID-19 Symptoms
A study led by the Duke Clinical Research Institute (DCRI) in partnership with Vanderbilt University found no differences in relief of mild-to-moderate COVID-19 symptoms between participants taking ivermectin and participants taking a placebo.
How to Manage the Next COVID Wave
Americans heading to the beach, backyard barbecues or long family road trips this summer might consider packing masks, test kits and a little common sense along with their swim trunks and sunscreen.
Why COVID-19 Boosters and Masking Remain Vital
As health experts brace for a potential COVID-19 surge this fall and winter, Dr. Carol Epling shares insights on how to stay safe.
Investigational Mucosal COVID Vaccine Protects Against Disease and Transmission
Hamster study found that a COVID vaccine designed to be taken as a pill results in neutralization of the SARS-CoV-2 virus in mucosal tissues
New Evidence Shows How COVID Can Hijack Human Kidney Cells
Duke researchers have shown that SARS-CoV-2 can infect kidney cells via multiple binding sites and use the cell’s machinery to replicate, causing injury and kidney disease. The discovery helps explain why acute kidney injury is one of the main complications observed in patients with severe COVID.
Vaccines & Countermeasures: Learning from COVID-19 and Planning for the Future
Duke in DC and Duke Health Government Relations convened a group of Duke experts to brief federal policymakers on the importance of federal investment in research, the impacts from their work, and additional recommendations to bolster our nation’s public health, medical preparedness, and response systems